Arbutus Biopharma vs Immunitybio
Immunitybio is the larger business, with $113m of revenue in fiscal 2025 against $14.1m for Arbutus Biopharma (8.0 times as much). Immunitybio grew faster (668.3% against 128.2%). Arbutus Biopharma kept more of each dollar of sales as profit: a net margin of -237.9% against -310.2%.
| Latest fiscal year | Arbutus BiopharmaABUS, 2025 | ImmunitybioIBRX, 2025 |
|---|---|---|
| Revenue | $14.1m | $113m |
| Revenue growth | 128.2% | 668.3% |
| Net income | −$33.5m | −$351m |
| Operating margin | -271.0% | -226.0% |
| Net margin | -237.9% | -310.2% |
| Return on equity | -38.5% | — |
| Free cash flow | −$39.6m | −$309m |
| Cash | $18.0m | $88.3m |
| Total debt | $0 | $326m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 19 | 691 |
| Market value | $791m | $8.37bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 16 sales |